These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 8402640)

  • 1. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
    Fan Z; Baselga J; Masui H; Mendelsohn J
    Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
    Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
    Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
    Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
    Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy.
    Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R
    Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
    Masui H; Kawamoto T; Sato JD; Wolf B; Sato G; Mendelsohn J
    Cancer Res; 1984 Mar; 44(3):1002-7. PubMed ID: 6318979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.
    Gao ZN; Wei YQ; Yang PS; Xu X; Zhao HQ; Huan X; Kang B
    Oral Oncol; 2007 May; 43(5):477-83. PubMed ID: 16997614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
    Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.